Showing 120 of 120on this page. Filters & sort apply to loaded results; URL updates for sharing.120 of 120 on this page
Small molecule AZD4635 inhibitor of A2AR signaling rescues immune cell ...
AZD4635 (HTL1071) is a Selective and Orally Active A2AR Antagonist ...
(PDF) Abstract LB-192: The A2AR antagonist AZD4635 prevents adenosine ...
AZD4635 is a potent A 2A R antagonist. (A) Chemical structure of ...
(PDF) Small molecule AZD4635 inhibitor of A 2A R signaling rescues ...
AZD4635 enhances immune activation and infiltration in vivo. (A) Mice ...
AZD4635 (HTL1071) | CAS 1321514-06-0 | AbMole BioScience | AZD4635 Price
Phase Ia/b, Open-Label, Multicenter Study of AZD4635 (an Adenosine A2A ...
A phase II study (AARDVARC) of AZD4635 in combination with durvalumab ...
A phase 2 study of AZD4635 in combination with durvalumab or oleclumab ...
AZD4635 enhances the antitumor activity of checkpoint inhibitors in ...
(PDF) Phase Ia/b, Open-Label, Multicenter Study of AZD4635 (an ...
The TST, CPT‐S‐PEG, and AZD4635 were co‐assembled into nanoparticles ...
AZD4635 | Adenosine Receptor | TargetMol
Multikilogram-Scale Preparation of AZD4635 via C–H Borylation and ...
Imaradenant (AZD4635) | Adenosine Receptor antagonist | CAS 1321514-06 ...
Sosei Heptares receives $15m for cancer therapy milestone
Frontiers | Evaluation of Combination Strategies for the A2AR Inhibitor ...
| Evaluation of combination strategies for AZD4635. (A) Identification ...
阿斯利康新药AZD4635 显著改善前列腺癌免疫治疗|前列腺癌|阿斯利康|血液腺苷|抵抗性|PFS|新药|免疫|胶囊|-健康界
(PDF) Evaluation of Combination Strategies for the A2AR Inhibitor ...
(PDF) Anti-tumor synergy evaluation of an AZD4635/anti-PD-L1combination ...
Small Molecules Drive Big Improvements in Immuno‐Oncology Therapies ...
Opportunities for Small Molecules in Cancer Immunotherapy: Trends in ...
Adenosine Signaling Is Prognostic for Cancer Outcome and Has Predictive ...
In vivo modulation of the adenosine pathway reduces tumor growth and ...
Small molecule-based immunomodulators for cancer therapy - PMC
Frontiers | Adenosine-A2A Receptor Pathway in Cancer Immunotherapy
Clinical cancer immunotherapy: Current progress and prospects - PMC
Synthetic Route Design of AZD4635, an A2AR Antagonist | Organic Process ...
Frontiers | Clinical cancer immunotherapy: Current progress and prospects
Publications – leadXpro
RCSB PDB - 6GT3: Crystal Structure of the A2A-StaR2-bRIL562 in complex ...
Structures of A 2A AR antagonists in clinical trials for cancer ...
Adenosine-A2A Receptor Pathway in Cancer Immunotherapy - PMC
Conversion of ATP to adenosine by CD39 and CD73 in multiple myeloma can ...
Targeting the adenosinergic axis in cancer immunotherapy: Insights into ...
A phase I, open-label, multicenter study to assess the safety ...
Immunosuppressive immune subpopulations are modulated following ...
Current Adenosinergic Therapies: What Do Cancer Cells Stand to Gain and ...
A new article was published in Frontiers in Immunology journal. - M&S
Investigation of immunotherapy effect of different nanoparticles in ...
Safety and pharmacokinetics of imaradenant (AZD4635) in Japanese ...
Op 80 Mg Beige
Adenosine A2A receptor as a potential target for improving cancer ...
(PDF) Safety and pharmacokinetics of imaradenant (AZD4635) in Japanese ...
A2B adenosine receptor antagonists rescue lymphocyte activity in ...
抗肿瘤腺苷A2A受体拮抗剂候选药物12o•2HCl- X-MOL资讯
Phase II trial of circulating cytokines as markers of docetaxel (DTX ...
Iridium- and Palladium-Based Catalysts in the Pharmaceutical Industry
Tumor Immunotherapy Using A2A Adenosine Receptor Antagonists
